.svg)
Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market
Venture Medical, LLC, a leading provider of advanced wound care solutions, is proud to announce a strategic development and distribution agreement in principle with Plasmacure B.V., the Netherlands-basedMedTech innovator behind the revolutionary PLASOMA cold plasma system for chronic wound treatment.
This agreement will introduce a new technology that has already demonstrated strong results in promoting wound healing to the UnitedStates. Under the terms of the agreement, Venture Medical will lead the FDA approval process. Once regulatory approval has been secured, Venture Medical will serve as Plasmacure’s exclusiveU.S. commercialization partner, supporting market entry, clinician education, and nationwide distribution of the CE-marked PLASOMA cold plasma device.
“The Plasoma cold plasma system represents the kind of patient-first innovation our industry needs,” said John Schroeder, VentureMedical CEO. “At Venture Medical we are willing to invest in long-term solutions for patients who currently have few good options for treating difficult-to-heal wounds.”
Plasmacure’s PLASOMA system delivers cold plasma derived from room air directly to chronic wounds through a unique flexible pad, safely initiating multiple mechanisms of action which are well known to speed healing. As rates of diabetic foot ulcers and other non-healing wounds continue to rise in the U.S., this system will offer a timely and effective response.
More details about the commercial path for PLASOMA and educational initiatives around the technology are forthcoming.
To learn more about PLASOMA or to learn more about the ability to partner with Venture Medical, visit www.venturemedical1.com or www.plasmacure.nl.
.png)
Innovation & Adaptability: An Interview with the CEO of Venture Medical,LLC
In an industry where innovation and adaptability are key, Venture Medical, LLC has carved out a unique space, blending bold ambition with a steadfast commitment to quality and service. Over the past few years, the company has experienced exponential growth, but what truly sets Venture apart isn’t just its expansion—it’s the culture, leadership philosophy, and relentless pursuit of excellence that fuel its success.
The Scrutiny on Skin Substitutes: Shifting The Focus From Medicare Advantage
While the top six major insurance companies have reported soaring profits—some rising by thousands of percentage points since the Medicare Advantage program was enacted, many patients enrolled in Medicare Advantage plans claim they didn’t even realize they were leaving traditional Medicare. This lack of transparency raises important questions about how these plans are marketed and the tactics used to encourage patients to switch.
The Rising Costs of Wound Care: Finding Solutions Without Sacrificing Access
Under a system previously reliant solely on hospital outpatient departments, many patients—especially the elderly in care facilities, the poor, the homebound, the rural, and the otherwise disenfranchised—never enjoyed equitable access. Today, however, more patients than ever are receiving wound care as providers are motivated to bring advanced modalities directly to them.
MicroGen Diagnostics in Chronic Wounds
“Explore the fascinating realm of microbiology and healthcare in the MicroGenDX Mic’d Up podcast, hosted by Rick Martin, CEO of MicroGenDX. Join Rick and his special guest, the esteemed Caroline Fife, MD, FAAFP, CWS, Professor of Medicine at Baylor College of Medicine
.png)
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions
The national ASP publication of AmnioWrap2™ knocks down barriers that will provide healthcare professionals and their patients with the opportunity to use AmnioWrap2™, a superior wound care product for certain applications.
